FMP
Leap Therapeutics, Inc.
LPTX
NASDAQ
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
2.46 USD
-0.09 (-3.66%)
2023
2022
2021
2020
0
0
1.5M
1.5M
427k
415k
0
0
-427k
-415k
1.5M
1.5M
86.61M
54.71M
41.7M
29.81M
73.23M
44.97M
32.16M
20.42M
13.38M
11.8M
10.77M
9.62M
-427k
0
0
0
13.81M
11.8M
10.77M
9.62M
0
-2.05M
-1.23M
-231k
-87.04M
-56.76M
-41.43M
-28.54M
5.63M
2.31M
815k
1.02M
-81.41M
-54.45M
-40.61M
-27.52M
0
147k
-24k
-2k
-81.41M
-54.6M
-40.59M
-27.51M
-3.98
-4.82
-4.73
-4.64
-3.98
-4.82
-4.73
-4.64
20.45M
11.32M
8.58M
5.93M
20.45M
11.32M
8.58M
5.93M
-80.99M
-53.98M
-40.01M
-26.81M
2023
2022
2021
2020
-318.17M
-263.57M
-222.99M
-195.17M
-81.41M
-54.6M
-40.59M
-27.51M
-1k
0
0
0
0
0
0
-303k
-399.58M
-318.17M
-263.57M
-222.99M
-81.42M
-54.6M
-40.59M
-28.12M
2023
2022
2021
2020
262k
689k
495k
593k
427k
415k
556k
668k
0
0
0
0
-165k
274k
-61k
-75k
2023
2022
2021
2020
0
0
0
0
0
0
0
0
0
0
0
0
All figures are in USD.